Receive The Newest Study Notifications

Myoscience, Inc., a medical device company dedicated to relieving pain through targeted therapies, today announced clinical trial results demonstrating that iovera° therapy significantly reduced the use of opioids following total knee arthroplasty (TKA) surgery...

  FDA accepts study protocol, providing green light for GENFIT to initiate Phase 2 clinical trial in pediatric NASH Elafibranor, the first molecule with positive results on registrational endpoint in Phase 2b clinical trial in adult NASH to be evaluated in...

Following last year’s stellar initial public offering in October, where it raised $80.5 million, about $10 million over initial expectations, LogicBio Therapeutics is planning a gene-editing clinical trial in children. Based in Cambridge, Mass., LogicBio focuses on...

CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company”) a late stage biotechnology company developing a novel humanized CCR5 monoclonal antibody for multiple therapeutic indications, today announced that leronlimab (PRO 140), its lead investigational CCR5 inhibitor,...

A clinical trial evaluating the safety and efficacy of an investigational drug for late-stage liver disease is now available at the Marshall University Joan C. Edwards School of Medicine. "The most serious liver complication of obesity is Non-Alcoholic...

Resultscould support a marketing application for an expanded U.S. indication forimprovement of sexual function in women ENGLEWOOD, CO / ACCESSWIRE / March 11, 2019 / Viveve Medical, Inc. (NASDAQ: VIVE), a medical technology company focused on women’s intimate health,...

Cynata Therapeutics Limited (ASX: CYP), a clinical-stage biotechnology company specialising in cell therapeutics, is pleased to announce that it has received favourable advice from the Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom,...

In a release issued under the same headline earlier today by Sorrento Therapeutics, Inc. (Nasdaq: SRNE), please note that in the subheadline the year the Phase 2 study will start should be 2019, not 2020 as previously stated. The corrected release follows: Yuhan...

- Donald B. Kohn, M.D., of UCLA to lead U.S. clinical development efforts for Leukocyte Adhesion Deficiency-I and Infantile Malignant Osteopetrosis programs - -Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) (“Rocket”), a leading U.S.-based multi-platform gene therapy...

ConSynance Therapeutics, Inc., a clinical-stage biotechnology company developing two innovative treatments for Prader-Willi Syndrome (PWS), today announced that they joined the PWS Clinical Trial Consortium. The PWS Clinical Trial Consortium (https://www.pwsctc.org/)...

Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, today announced that the first patient has been...

Patients experience earlier returns to function following total knee replacement surgery by using new app-driven muscle strengthening device CyMedica Orthopedics®, the leading combined digital health and muscle strengthening therapy developer, today announced...

ExThera Medical Corporation (ExThera) today announced the formation of its Scientific Advisory Board. Led by chairman Lakhmir (Mink) Chawla, MD, current Chief Medical Officer of La Jolla Pharmaceutical Company, the Scientific Advisory Board will include several...

ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, today announced the first patient dosed in the Phase 1/2 STELLAR clinical trial for...

  25-point (42%) mean improvement in the UPDRS Part III (motor) OFF score, with individual patient improvements of 14 points and 36 points respectively Benefit seen across all UPDRS OFF subscales at 3 months Reductions in ON state dyskinesias seen on the Rush...

Rubius Therapeutics, Inc. (Nasdaq:RUBY), a biopharmaceutical company that is generating red blood cells and bioengineering them into an entirely new class of cellular medicines, today announced that the U.S. Food and Drug Administration (FDA) has cleared the company’s...

This trial will evaluate the efficacy of AVID100 in SCCHN patients with EGFR IHC 3+ tumors AVID100 is the most advanced, broadly active anti-EGFR ADC in clinical development 20% of SCCHN patients highly overexpress EGFR; no therapy is approved for these patients...

TB Alliance's new drug application (NDA) for the novel tuberculosis (TB) drug candidate pretomanid has been accepted for review by the United States Food and Drug Administration (FDA). The application is for the use of pretomanid as part of a new regimen, in...

Clinical trials are the pathway for new drugs or devices to enter the U.S. and other worldwide markets. However, not all clinical trials are the same. A recent article by a 20+ year insider in the clinical trial industry said: "While clinical trials for medical...

SOTIO, a biotechnology company owned by the PPF Group, today announces that final data from the SOV02 Clinical Trial with DCVAC/OvCa will be presented in the plenary session as an oral presentation at the 2019 SGO’s 50th Annual Meeting on Women's Cancer. Final...